Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer

Kyu Kim, Yong Joon Lee, Tae Hoon Kim, Jae Sun Uhm, Hui Nam Pak, Moon Hyoung Lee, Boyoung Joung

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background and Objectives: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fbrillation (AF) patients with cancer. We aimed to assess the efcacy and safety of NOACs in AF patients with cancer in this study. Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. Based on propensity score matching, 388 matched pairs were included in the NOAC and warfarin groups. Results: Patient baseline characteristics were comparable between the matched groups. During median follow-up of 1.8 years, the NOAC group had signifcantly lower incidences of ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than the warfarin group. Moreover, the incidence of major bleeding was signifcantly lower in the NOAC group than in the warfarin group with optimal international normalized ratio control (p=0.03). Especially, within 1 year afer cancer diagnosis, the incidences of all clinical events were signifcantly lower in the NOAC group than in the warfarin group. Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year afer cancer diagnosis.

Original languageEnglish
Pages (from-to)406-417
Number of pages12
JournalKorean Circulation Journal
Volume48
Issue number5
DOIs
Publication statusPublished - 2018 May

Fingerprint

Anticoagulants
Atrial Fibrillation
Warfarin
Embolism
Neoplasms
Hemorrhage
Cause of Death
Stroke
Incidence
Propensity Score
International Normalized Ratio
Research Design
Safety

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Kim, Kyu ; Lee, Yong Joon ; Kim, Tae Hoon ; Uhm, Jae Sun ; Pak, Hui Nam ; Lee, Moon Hyoung ; Joung, Boyoung. / Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. In: Korean Circulation Journal. 2018 ; Vol. 48, No. 5. pp. 406-417.
@article{157120838deb4f408e90e99a3015fd2a,
title = "Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer",
abstract = "Background and Objectives: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fbrillation (AF) patients with cancer. We aimed to assess the efcacy and safety of NOACs in AF patients with cancer in this study. Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. Based on propensity score matching, 388 matched pairs were included in the NOAC and warfarin groups. Results: Patient baseline characteristics were comparable between the matched groups. During median follow-up of 1.8 years, the NOAC group had signifcantly lower incidences of ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than the warfarin group. Moreover, the incidence of major bleeding was signifcantly lower in the NOAC group than in the warfarin group with optimal international normalized ratio control (p=0.03). Especially, within 1 year afer cancer diagnosis, the incidences of all clinical events were signifcantly lower in the NOAC group than in the warfarin group. Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year afer cancer diagnosis.",
author = "Kyu Kim and Lee, {Yong Joon} and Kim, {Tae Hoon} and Uhm, {Jae Sun} and Pak, {Hui Nam} and Lee, {Moon Hyoung} and Boyoung Joung",
year = "2018",
month = "5",
doi = "10.4070/kcj.2017.0328",
language = "English",
volume = "48",
pages = "406--417",
journal = "Korean Circulation Journal",
issn = "1738-5520",
publisher = "Korean Society of Circulation",
number = "5",

}

Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. / Kim, Kyu; Lee, Yong Joon; Kim, Tae Hoon; Uhm, Jae Sun; Pak, Hui Nam; Lee, Moon Hyoung; Joung, Boyoung.

In: Korean Circulation Journal, Vol. 48, No. 5, 05.2018, p. 406-417.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of non-Vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer

AU - Kim, Kyu

AU - Lee, Yong Joon

AU - Kim, Tae Hoon

AU - Uhm, Jae Sun

AU - Pak, Hui Nam

AU - Lee, Moon Hyoung

AU - Joung, Boyoung

PY - 2018/5

Y1 - 2018/5

N2 - Background and Objectives: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fbrillation (AF) patients with cancer. We aimed to assess the efcacy and safety of NOACs in AF patients with cancer in this study. Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. Based on propensity score matching, 388 matched pairs were included in the NOAC and warfarin groups. Results: Patient baseline characteristics were comparable between the matched groups. During median follow-up of 1.8 years, the NOAC group had signifcantly lower incidences of ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than the warfarin group. Moreover, the incidence of major bleeding was signifcantly lower in the NOAC group than in the warfarin group with optimal international normalized ratio control (p=0.03). Especially, within 1 year afer cancer diagnosis, the incidences of all clinical events were signifcantly lower in the NOAC group than in the warfarin group. Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year afer cancer diagnosis.

AB - Background and Objectives: There are limited data on the use of non-vitamin K antagonist oral anticoagulants (NOACs) in atrial fbrillation (AF) patients with cancer. We aimed to assess the efcacy and safety of NOACs in AF patients with cancer in this study. Methods: In 2,568 consecutive non-valvular AF patients with newly diagnosed cancer, we analyzed ischemic stroke/systemic embolism (SE), major bleeding, and all-cause death. Based on propensity score matching, 388 matched pairs were included in the NOAC and warfarin groups. Results: Patient baseline characteristics were comparable between the matched groups. During median follow-up of 1.8 years, the NOAC group had signifcantly lower incidences of ischemic stroke/SE (p<0.001), major bleeding (p<0.001), and all-cause death (p<0.001) than the warfarin group. Moreover, the incidence of major bleeding was signifcantly lower in the NOAC group than in the warfarin group with optimal international normalized ratio control (p=0.03). Especially, within 1 year afer cancer diagnosis, the incidences of all clinical events were signifcantly lower in the NOAC group than in the warfarin group. Conclusions: In AF patients with newly diagnosed cancer, NOACs showed lower incidences of ischemic stroke/SE, major bleeding, and all-cause death than warfarin, especially within 1 year afer cancer diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=85046933847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046933847&partnerID=8YFLogxK

U2 - 10.4070/kcj.2017.0328

DO - 10.4070/kcj.2017.0328

M3 - Article

AN - SCOPUS:85046933847

VL - 48

SP - 406

EP - 417

JO - Korean Circulation Journal

JF - Korean Circulation Journal

SN - 1738-5520

IS - 5

ER -